us Lisa, you, and you, for Thank thank joining everyone, today.
closer the to seven kick to could we this I unfortunately, It's imagined. goal passed off, years long was been plan. journey join As XXXX beginning that it's of years have an was and MannKind because harder amazing it growth weekend ago play that Alan our away. anyone seven thrown than We decided was special and come the that to our future new is way us. against one
We foundation through this growth, our stakeholders our are next us employees, our want trustees who prepared and support all phase enter debt holders of and and stock capitalized other demand of to and to journey. I personally thank
best Our our us. very off excited in kick to call of years are earnings I'm QX front today.
patient from launch the V-Go more human Tyvaso feedback live. [indiscernible] we mission people This into is we to true is or day, as from human. or the as we refer more making To DPI's get present. as people's lives and stories remind we incredible get life well as to to Every life, their people the control health never freedom live give our are this to and right hear of we and more easier
for MannKind. revolutionary year was XXXX a
and revenue INHALE-X which If last for for just in FDA one approval clinical compound with Afrezza that DPI, marketed just commercial you we delay is look a at stream facing product. back this time Afrezza. trials, We're one year, a Tyvaso started had in
clinical the to marketed four that's and with commercial streams. we off we out kicking revenue trials year, and in Afrezza completing Therapeutics, United products, end and Phase one two two and INHALE-X rolled three compounds we halfway As marketed by market have X
of run to a and XXXX. the the is go talk translates $XXX XXXX we revolutionary Company as as pipestone will this approaching history the million exiting rate in we're that Steve look, we beyond. into As how about
step are up collaboration When XX% we our versus year. take a last royalties back,
business of exciting look states endocrine to to really be capital the continued continue with required a look Tyvaso you growth across to sources has and the new we're phases of this go It's versus revenue to was last Our up difference going for early these as When year. generate fund revolutionary three that to are disease servicing. These our quarter United through XX% drive states DPI's last at back launch. a Therapeutics. year, repeat we patients
the royalty productivity should we the services to collaboration of some And relatively revenue So reason collaboration and is early XQ, of for continues volume as the revenue quarter is continue the the fixed world see getting grow. to just in getting the or the QX, off And flat, you the market, of can ground but with off we're revenue just Therapeutics. United increase grow. that factory first SKUs continue is to this services you that's relatively the out important
in we as mind -- go minor something forward. not as that's keep look from dramatically quarter-to-quarter, So will to but different it fluctuate we
important, almost dropped million we you business look in incremental from to we The to net this grew to increase gross future XX% this dollar flat gross We'll XXXX. that bottom despite and is We've to any million as line. profit EBU combining here for accelerated revenue the continue business business into and company $XX drop V-Go. in our V-Go unit. associated it to able look bottom relatively to this keep $XX The XX% every growth. efficiency COGS and growth the starts did and without adding the on in cost driving When and with revenue, profit at reason the COGS with endocrine our look been at line
Additionally, we exited money to last repurposed business we the that which in future had a drive that small and being as didn't as planned pilot year is and last primary NPL. this care year, year growth go
me you the bit demand, more a future. manufacturing on is had to Let bring strong now which focus at QX little we into our DPI, When highlights. look agent revenue
royalty grew versus XX% Our QX. revenue
tour. in trial to The the FDA meeting as move expansion in have progress of Danbury moving we'll on during and share and QX. X/X capacity forward we a taking week, QX asset into one and manufacturing details since expect this half has XXXX, sometime just here design Phase we been one pipeline Our in more last is a more one, second
filed MannKind we request shortly the X and a for expect to here pre-IND meeting We feedback progress X.X, we a see into a study. team as Phase
our business, look sequentially at Afrezza grew 'XX diabetes As versus I quarter-to-quarter. and X% in X%
X on historically analysis as saw showed think first made of to capitalize with really we've position we about we results we've study but the Afrezza, the in us seen the do given meal diabetes. yesterday, Combination to seen the As a type X a Afrezza win in confidence and results results test, in investments track. on us and full already I so larger just have want we you will the leader we've to later be in presented But to far, off favorable will Phase announced how year. Basal be office kick study INHALE-X challenge said, a the this the dose And this really
cash stabilized last year. had you We million V-Go the that had it. in QX cash $XXX end of net business equivalents looking revenue and I show at and of we $X.X million. will to forward shortly,
continues stead to innovation seven Several With capitalize V-Go and the of and launch MannKind the is tried mealtime as they competition to and last the patient really years, to purchase over other the way, on company. meaningful failed insulins that solutions drive differences. their
we to drive they're long but and sets with have want this the the they what enough as mealtime Afrezza's and we believe to also will day challenge we fail of months, to point, And quality to new from innovation. of to and on life. us really the a happens try V-Go another solve ability pod, improvement believe go out see patients demonstrated solution that struggling terms patients type-X much really At have, continued have and test some mealtime in on market over better, also has fee companies and pump that help product the is coming and we Insulin to control. those help time this pump XX will one and allow that
we number our up which is of scientific really last of out one, we built The have these over last results or Some work they came the of year last put year the year's bolted into the last five understanding years. highlights Afrezza. be for really
at to something first the we mealtime X hope when that we about down each ABC And Xx months. our look results showed and so meal we're you the put pediatric but to in look versus translate does hours yesterday, as will for around INHALE-X two you it dosing think you just over to X trial, round was released amazing route that's XX off dosing that into out care first we dividends the using control, And that as paying were injectables. really really Afrezza believe in dose the at
of DAS we've trial Hopefully, already will come dose. we've the which submitted insert published and package future was analysis ABC study, doubling conferences, additional The out. our
we've Our remains shown additional to no pediatric mealtime pump can but that pump hopefully, you, progress, and continue insulin people who improve will great, we'll there's also study despite an showing show And Afrezza. adding safely on from Afrezza how to a adding people to are it benefit data control. help switch is
agent support On enhanced Afrezza, we've our services.
of insulin Inflation support, that company the Protection that around efficiency few happens TS to drug gap patients Medicare probably that on ways for and and coverage. the the patient holders find really of to prior I'm We're it in friction in included Act, did including several one ensure continue supportive and inhalants help were who years reimbursement We fact because to apartments. with executives was the authorization
of people and over not the And dating demand reason returns allowed makes up as for which related may have and to sense XX months from believe dating, will are percentage time. product product realize time, happen important gross nets the our that's improved good picks our XX returns, also the come That a we is We months. to tell.
we purchased XXXX we this entire focus just second asset being V-Go, in we as that MannKind. is year, now launched for and quarter. And On our integration, for into force. prepared We may QX Keppra sales this through Afrezza the team of it at finally, within this integrated the
where NRx to we you growth market on year One key of NRxs. grow driving QX through with from of QX, see focuses share growth last can XX% our continued quarter-over-quarter our year-over-year new exited prescriptions. And was
our this year. six at the for of date, growth XX% weeks just As I look QX over QX QX to versus first
momentum continue how translates We indicator perform. our positive this we leading business to of expect [indiscernible] is to TRxs our over see time, on which to but
NRx, positioned look got V-Go, QX can look purchased As been QX, QX real we expect we you on We look here on to decline. to in critical segment this Afrezza V-Go stabilizing forward stabilizing in has back products to as and NRxs, a most now at in again, in and long rest to of it asset TRx commercial to NRxs grow ready importantly, look will insurance. growing that the But for type ultimately success. two [indiscernible] X We've population, we year. our to QX. is really translate and this younger these
because are day, we market type have the But win Medicare, and now on diabetes. we though lead to Even X that's Medicare. want sales to is our Medicare, end of make XX% at sure of the continue we XX% great
specialty improve that purchase our to pharmacy our direct continue when have find sure to a patients product. sales better we to net ways making by service to gross shifting through our they and agreements receive Additionally,
put V-Go it's asset. definitely older a On position product, Medicare X in XXXX, type which this of territory And this V-Go case V-Go. it's selling XX% in and now side, future a the about for we've the potential is Afrezza in population,
XX XX Number one, ridge several of we coming over kickoff InHealth As have next we look mantras AATD. the has there are to occurred really months, out. the with key
to device We will technology first to to technology the how This read dosing. along into launch, start care. is Dupi integrating incorporate behind we a continue will about our which and as a really we think have start invest our that of to which grow BluHale is as predictive a and kind CGM that future platform Afrezza X.X that to AI version, into with diabetes platform be CGM in attach
We X full year. here month we're a in well. trial, calling then to type X We the of launch out assuming with second limited diabetes. the BluHale, Phase which a And goes expect the read started simply INHALE-X just half
this of and end We and sometime year, expect the of should year the INHALE-X enrolled study but the to be end early later. year three the INHALE-X follow pediatric about next readout deploying by in months the
to who's turn last it the Steve with Now partner over I'm phenomenal a me to going six over years.
Steve. you, Thank
